Background: Travelers' diarrhea causes significant morbidity including some sequelae, lost
travel time and opportunity cost to both travelers and countries receiving travelers. Effective …

Shigellosis is a global human health problem. Four species of Shigella ie S. dysenteriae, S.
flexneri, S. boydii and S. sonnei are able to cause the disease. These species are …

THE introduction of fluoroquinolone antimicrobial agents (Fig. 1) into clinical use is an
important recent advance. 1-3 These drugs, also called quinolones, include norfloxacin …

Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America | Clinical
Infectious Diseases | Oxford Academic Skip to Main Content Advertisement Oxford Academic …

During the past 10 years there have been some major improvements in our knowledge base
regarding the treatment of infectious diarrhoea. Oral rehydration therapy (ORT) remains …

Background Shigella dysentery is a relatively common illness and occasionally causes
death, worldwide. Mild symptoms are self‐limiting but in more severe cases, antibiotics are …

Of the millions who travel from the industrialized world to developing countries every year,
between 20% and 50% will develop at least one episode of diarrhea, making it the most …

Background: Treatment of shigellosis is currently limited by the high prevalence of multidrug-
resistant strains of Shigella. Objective: To determine the efficacy of azithromycin in the …

Objectives Reducing antibiotic consumption has now become a major public health priority.
Reducing treatment duration is one of the means to achieve this objective. Guidelines on the …

▪ Objective: To evaluate the clinical and microbiologic efficacy and safety of norfloxacin for
acute diarrhea.▪ Design: Double-blind, placebo-controlled, randomized clinical multicenter …